VERAXA Biotech AG (NASDAQ: VRXA) has appointed Carl von Halem as interim chief financial officer, effective immediately, as the company transitions its finance leadership. Von Halem succeeds Torsten Bürgermeister and will oversee the finance function while VERAXA finalizes discussions with a permanent CFO candidate, whom the company expects to support its next phase of expansion and operational growth. An update on the permanent appointment is expected in due course.
Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA’s public listing. The company cited his extensive experience in corporate finance, life sciences, and technology-driven businesses, along with his familiarity with VERAXA’s operations and strategic development, as key qualifications for leading the finance function during this transition. His appointment ensures continuity in financial leadership as the company advances its pipeline of next-generation antibody-based therapeutics.
VERAXA Biotech is focused on building a premier engine for the discovery and development of antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is powered by transformative technologies and guided by rigorous quality-by-design principles, rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. Founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), VERAXA leverages world-renowned research to drive innovation.
The announcement of the interim CFO appointment underscores VERAXA’s commitment to maintaining strong financial governance as it scales operations. The company’s ability to attract experienced leadership like von Halem, who has deep ties to its public listing process, signals confidence in its strategic direction. Investors may view this transition as a positive step toward securing long-term financial leadership aligned with growth objectives.
For more details, the full press release is available at https://nnw.fm/BjjY6. Additional updates on VERAXA Biotech can be found in the company’s newsroom at http://nnw.fm/VRXA.
